FRANKLIN LAKES, N.J.,
Nov. 21, 2019 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced its latest advancement
in combating antimicrobial resistance (AMR) with new analytics
integrated into the company's connected medication management
platform that identifies when an inappropriate and potentially
ineffective antibiotic has been prescribed, based on a patient's
specific infection diagnosis.
There is a heightened focus on antimicrobial stewardship across
the health care industry with new reimbursement standards released
by Centers for Medicare & Medicaid Services (CMS) requiring
hospitals to comply with certain infection prevention and
antimicrobial stewardship requirements.1,2 Additionally,
the Centers for Disease Control and Prevention (CDC) released its
updated "Threat Report" – noting antibiotic-resistant bacteria and
fungi cause more than 2.8 million infections and 35,000 deaths in
the United States each
year.3 Despite public transparency, heightened
awareness and financial penalties, hospitals continue to struggle
with the burden of health care associated infections (HAIs) and
AMR. To help combat these challenges, BD will unveil new
antimicrobial stewardship functionality within the BD HealthSight™
connected medication management platform at this year's American
Society of Health-System Pharmacists (ASHP) Midyear Meeting being
held in Las Vegas from
Dec. 9-11.
BD HealthSight™ Clinical Advisor is a new functionality within
the BD HealthSight™ connected medication management platform that
aggregates disparate patient data to provide clinicians with the
ability to receive near real-time medication stewardship alerts
within the pharmacy workflow. These actionable alerts are delivered
within the connected medication management process to help health
care providers prevent not only the administration of inappropriate
antibiotics, but also the potential waste of resources associated
with compounding and preparing unnecessary medication for delivery.
Clinical stewardship programs are also supported through customized
dashboards, robust reports and the ability to automate the
submission of antimicrobial utilization data for regulatory
reporting.
"BD is uniquely positioned to deliver some of the most
innovative strategies to address the systemic issues associated
with medication management," said Ranjeet
Banerjee, worldwide president of Medication Management
Solutions for BD. "We continue to develop actionable solutions to
complex health issues that require a multifaceted approach, such as
AMR and hospital drug diversion. Our latest advancement in
antimicrobial stewardship is a fundamental example of our
dedication to help health care workers improve patient
outcomes."
Since introducing the BD HealthSight™ platform in 2017, BD has
expanded and strengthened its offerings of connected technologies,
advanced analytics and expert services. This approach includes
centralized enterprise-wide analytics, powered by artificial
intelligence (AI) in specific use cases, across BD products and
connectivity between BD Pyxis™ and BD Alaris™ technologies, in
addition to connectivity into the electronic medical record (EMR).
Added capabilities such as antimicrobial stewardship surveillance
and analytics are the result of this truly integrated system,
designed with the clinician in mind to help improve efficiencies
and outcomes – with the goal of affording more time for health care
workers to focus on patient care.
"One of the key weapons in the fight against the growing problem
of drug resistant bacteria is effective antimicrobial stewardship
in hospitals. Using available antimicrobials appropriately is the
only way to maintain their effectiveness long term and avoid
collateral damage, which in turn has the ability to help reduce
healthcare associated infections," said Dr. Fares Khater, system
director of infectious diseases at Appalachian Regional Healthcare
Corporation. "The ability to have near real-time visibility into
medication stewardship alerts will enable our staff to make more
informed decisions quickly that have the potential to improve
patient outcomes by avoiding specific antibiotics when
appropriate."
BD's AMR strategy addresses the need for a multifaceted approach
to curbing the threat of AMR, including the immediate need for
advancement in infection prevention and control practices,
diagnostics and surveillance tools. BD engages in extensive
cross-sector collaboration with leading health agencies,
foundations and other organizations around the world to deploy
training initiatives, information systems and medical technology
that support programs in hospitals and laboratories, tailoring its
approach to the stage of development and level of sophistication in
each country's efforts to combat AMR. These new integrated
capabilities in the BD HealthSight™ platform are the latest in BD
infection surveillance technology. Other BD infection surveillance
offerings include data mining technology that creates an early
warning system to detect infection anomalies before an outbreak
occurs and tools for health care facilities to easily report
infection data electronically to public health authorities for
enhanced monitoring to identify local, regional and national
trends.
BD invites conference attendees to visit booth #1637 to
learn more about scaling medication management to the enterprise
level with a comprehensive approach that links hospitals'
technologies, workflows, inventory and clinical decisions involved
in medication therapies across the care continuum. For a complete
list of exclusive BD in-booth speaking sessions, symposia
sponsorships and other conference activities, please visit
bd.com/ASHP2019 and follow BD on Twitter @BDandCo for live
conference updates.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 65,000
employees have a passion and commitment to help enhance the safety
and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com.
1Centers for Medicare & Medicaid Services (CMS)
State Operations Manual Appendix A - Survey Protocol, Regulations
and Interpretive Guidelines for Hospitals, Rev. 183, 10-12-18.
https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/som107ap_a_hospitals.pdf
2Department of Health and Human Services & Centers
for Medicare & Medicaid Services (CMS). Federal Register, Vol.
84, No. 189, 9-30-19, Rules and Regulations.
https://www.govinfo.gov/content/pkg/FR-2019-09-30/pdf/2019-20736.pdf
3U.S. Department of Health and Human Services: Centers for
Disease Control and Prevention. Antibiotic Resistant
Threats In The United States;
2019.
Contacts:
|
|
Public
Relations:
|
Investor
Relations:
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
858.617.2361
|
201.847.5378
|
Troy.Kirkpatrick@bd.com
|
Monique_Dolecki@bd.com
|
View original
content:http://www.prnewswire.com/news-releases/bd-launches-enhanced-antimicrobial-stewardship-analytics-capabilities-300962427.html
SOURCE BD (Becton, Dickinson and Company)